Last reviewed · How we verify
azathioprine or adalimumab and infliximab
azathioprine or adalimumab and infliximab is a Immunosuppressant combination (purine analog + TNF-α inhibitors) Small molecule drug developed by Tokyo Medical and Dental University. It is currently in Phase 3 development for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Rheumatoid arthritis, Other TNF-α-responsive autoimmune conditions.
This is a combination therapy using azathioprine (an immunosuppressant) alongside TNF-alpha inhibitors (adalimumab and/or infliximab) to suppress immune-mediated inflammation.
This is a combination therapy using azathioprine (an immunosuppressant) alongside TNF-alpha inhibitors (adalimumab and/or infliximab) to suppress immune-mediated inflammation. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Rheumatoid arthritis, Other TNF-α-responsive autoimmune conditions.
At a glance
| Generic name | azathioprine or adalimumab and infliximab |
|---|---|
| Sponsor | Tokyo Medical and Dental University |
| Drug class | Immunosuppressant combination (purine analog + TNF-α inhibitors) |
| Target | TPMT/HGPRT (azathioprine); TNF-α receptor (adalimumab and infliximab) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Azathioprine is a purine analog that inhibits T and B cell proliferation, while adalimumab and infliximab are monoclonal antibodies that block tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine. Together, this combination targets multiple pathways of immune activation to reduce inflammatory disease activity.
Approved indications
- Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- Rheumatoid arthritis
- Other TNF-α-responsive autoimmune conditions
Common side effects
- Infection (bacterial, viral, opportunistic)
- Bone marrow suppression / leukopenia
- Hepatotoxicity
- Nausea / gastrointestinal upset
- Infusion reactions (TNF inhibitors)
Key clinical trials
- An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis (PHASE2)
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- Post-Operative Crohn's Disease Outcome in Children
- Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib (PHASE4)
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
- Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- azathioprine or adalimumab and infliximab CI brief — competitive landscape report
- azathioprine or adalimumab and infliximab updates RSS · CI watch RSS
- Tokyo Medical and Dental University portfolio CI
Frequently asked questions about azathioprine or adalimumab and infliximab
What is azathioprine or adalimumab and infliximab?
How does azathioprine or adalimumab and infliximab work?
What is azathioprine or adalimumab and infliximab used for?
Who makes azathioprine or adalimumab and infliximab?
What drug class is azathioprine or adalimumab and infliximab in?
What development phase is azathioprine or adalimumab and infliximab in?
What are the side effects of azathioprine or adalimumab and infliximab?
What does azathioprine or adalimumab and infliximab target?
Related
- Drug class: All Immunosuppressant combination (purine analog + TNF-α inhibitors) drugs
- Target: All drugs targeting TPMT/HGPRT (azathioprine); TNF-α receptor (adalimumab and infliximab)
- Manufacturer: Tokyo Medical and Dental University — full pipeline
- Therapeutic area: All drugs in Immunology / Rheumatology
- Indication: Drugs for Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Other TNF-α-responsive autoimmune conditions
- Compare: azathioprine or adalimumab and infliximab vs similar drugs
- Pricing: azathioprine or adalimumab and infliximab cost, discount & access